Home » Posts tagged with » Cancer immunotherapy
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]

Cancer immunotherapy company EpicentRx raises $35m in Series D round

EpicentRx, a cancer immunotherapy company based in California, has secured $35 million of capital through a Series D financing round to support the development of small molecule immunotherapy and its oncolytic viral platform. The oncology company used the services of Biotech Alliances International, a Silicon Valley based life-science focused investment bank to get the funding. […]

Continue reading …
MicroMedicine to introduce new white blood cell isolation technology at SITC annual conference

MicroMedicine, a US life sciences technology company, will launch Sorterra Cell Isolation System, a white blood cell isolation technology, at the 34th Society for Immunotherapy of Cancer (SITC) annual conference to be held from November 6-10 in National Harbour, Maryland. Sorterra Cell Isolation System will separate white blood cells from human peripheral blood preserving sample […]

Continue reading …
Compugen kickstarts phase 1 trial of cancer immunotherapy COM701

Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]

Continue reading …